Applied Biosystems, part of Life Technologies Corporation (NASDAQ: LIFE), and Chromsystems Instruments & Chemicals GmbH today announced joint solutions for the clinical research field. These solutions provide complete, integrated workflows to simplify mass spectrometry technology for a variety of clinical research applications, such as therapeutic drug monitoring.
These solutions are expected to accelerate the adoption of new tests, including vitamin D, amino acids, acylcarnitines, immunosuppressants, antidepressants and neuroleptics, for medically-relevant research. These types of studies often lead to validated diagnostic tests, which are used in regulated laboratories. By combining Chromsystems' validated reagent kits, calibrators and controls with SCIEX mass spectrometers and software, the new solutions enable clinical researchers to broaden the use of mass spectrometry for their research, providing faster and more comprehensive results than alternative technologies, while ensuring compliance with industry standards.
To deliver these solutions in a uniquely integrated, efficient way, Applied Biosystems is expanding its offerings of application-specific iMethodTM Tests, which are pre-configured methods for laboratory use. New iMethod Tests for clinical researchers are designed to optimize Chromsystems' specialized chemistries on SCIEX triple quadrupole and QTRAP® LC/MS/MS systems. These are supported by an enhanced version of ChemoViewTM Software to simplify data interpretation. These systems, software and test methods were developed by the Applied Biosystems/MDS Analytical Technologies joint venture. Laura Lauman, President of Life Technologies' Mass Spectrometry Systems Division "Life Technologies is actively working to help advance clinical research through the expanded use of mass spectrometry technologies. We are responding to the growing demand in this market for more integrated and simplified solutions that enhance medical studies." Michael Meier, Managing Director of Chromsystems "Chromsystems continues to provide clinical laboratories with optimized solutions by developing customized sample preparation and analysis assays. We are redefining how reagents and consumables can add to the precision, reliability and ease of work on a mass spectrometry system. Our agreement with Applied Biosystems is the next step in our efforts to reinforce the confidence that clinical laboratories have in us to work with a leader in mass spectrometry instrument solutions for superior laboratory results."
Additional Resources Clinical Research Solutions Chromsystems Product Overview Mass Spectrometry Overview
About Applied Biosystems Products Life Technologies
Applied Biosystems brand is a global leader in providing innovative, optimized instrument systems and workflows to accelerate academic and clinical research, drug discovery and development, pathogen detection and forensic DNA analysis. Through its Applied Biosystems and Invitrogen brand of reagents, kits and bench-top devices, Life Technologies markets the most comprehensive portfolio of solutions for molecular and cell biology. Applied Biosystems and Invitrogen products are used in nearly every major laboratory in the world.
About Chromsystems Products
For nearly 20 years, Chromsystems products have linked high technology with the needs of clinical laboratories worldwide. Combining the technical advantages of LC-MS/MS with the smooth workflow of reagent kits, quality controls and calibration standards, Chromsystems products add value to laboratories, providing results with less effort, more reliability and fulfilling regulatory rules with ease. Each analysis Chromsystems offers is validated and optimized for mass spectrometry and focuses on the analyte in question.
Having started with the HPLC technique, Chromsystems products have grown into mass spectrometry in the last several years and have gained equally high reputation for easy application, fast evaluation and premium results.
About Life Technologies Life Technologies Corporation
Life Technologies Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of more than $3 billion in 2008, employs approximately 9,500 people, has a presence in more than 100 countries, and possesses a rapidly growing intellectual property estate of approximately 3,600 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc.
Life Technologies Safe Harbor Statement This press release includes forward-looking statements about Life Technologies' anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.